1172 Genetic Variation in Il28b Rs 12979860 and Response to HCV-Specific Treatment in HCV/Hiv Co-Infected Patients

Nischalke, HD; Vogel, Martin; Michalk, M.; Mauss, S; Baumgarten, Axel; Naumann, Uwe; Stellbrink, Hans Jürgen; Danta, Mark; Tural, C.; Bruno, Raffaele; Krämer, Bernhard K.; Körner, Christian; Schulte, Daniela; Eisenhardt, M; Glässner, A; Sauerbruch, Tilman; Rockstroh, JK; Spengler, Ulrich; Nattermann, Jacob

doi:10.1016/s0168-8278(10)61173-7

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…rs12979860 appeared to influence response in HCV genotype 1, but not genotype 2/3 patients, similar to what was observed by Rauch et al [11,16]. Nischalke et al [17] presented data at the European Association for the Study of Liver 2010 meeting confirming these observations, but more interestingly, noted that there was no significant difference in treatment responses according to IL28 genotype during acute HCV infection in the context of HIV co-infection. These observations emphasize the need for further research on the role of IL28B, both in the context of HIV infection and in particular, during acute HCV infection more generally.…”

Section: Treatment Of Hepatitis C Virus Infectionsupporting

confidence: 77%

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

2010

View full text Add to dashboard Cite

Three landmark genome-wide association studies (GWAS) published in 2009 identified the interleukin (IL) 28B gene locus as pivotal to the pathogenesis of hepatitis C virus (HCV) infection. Polymorphisms near the IL28B gene not only predicted treatment-induced and spontaneous recovery from HCV infection, but they also explained, to some extent, the difference in response rates between Caucasians and African Americans to standard therapy with pegylated interferon and ribavirin. The revelation that IL28B, an innate cytokine, plays an essential role in the pathogenesis, outcomes, and treatment responses to HCV infection has triggered a gold rush and an ever increasing number of reports on the subject are being presented at international conferences and in scientific journals. This review will summarize currently available data on the clinical impact of IL28B polymorphisms on HCV infection and the potential mechanisms for its effects. It will conclude with a discussion on how the research observations may translate into clinical practice and drug development.

show abstract

Section: Treatment Of Hepatitis C Virus Infectionsupporting

confidence: 77%

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

2010

View full text Add to dashboard Cite

show abstract

“…Estos resultados inicialmente se comprobaron entre los pacientes monoinfectados por el VHC si bien también se han corroborado ya en coinfectados por VIH-VHC. En los coinfectados, se han publicado varios estudios y en 2 de ellos se constata la importancia de estos polimorfismos en la predicción de la respuesta al tratamiento del VHC genotipo 1 pero no en los genotipos 2 o 3, mientras que en el tercero no se evidencia esta predicción en el tratamiento de la hepatitis aguda 53,54 . El hallazgo de este marcador genético y su clara implicación en la clínica es un excelente ejemplo de la aplicación directa de la ciencia básica a la práctica médica habitual.…”

Section: Nuevos Aspectos De La Hepatitis C En Pacientes Infectados Pounclassified

Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana

Masferrer¹,

Martı́nez-Rebollar²,

Laguno³

2011

Gastroenterología y Hepatología

View full text Add to dashboard Cite

“…As in HCV monoinfected patients, a SVR is associated with no progression of disease and related to liver histological improvement, which reduces the occurrence of liver decompensation or hepatocarcinoma [32][33][34]. The HCV genotypes are related to a better SVR after treatment.…”

Section: Introductionmentioning

confidence: 99%

HIV/HCV Coinfection: Considerations about Treatment

Komninakis¹

2014

J Med Microb Diagn

View full text Add to dashboard Cite

Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Infections are considered public health problems. The coinfection HIV/HCV is common in individuals exposed to parenteral exposure, and HVC has emerged as the leading cause of deaths among HIV-1-seropositive patients. The treatment of HIV/HCV coinfected people should be able to suppress viral replication for both viruses, with the purpose of to improve the immunological response and include liver damage. These two aspects should be associated with a high safety profile, because the toxicity of antiretroviral drugs used to treat HIV in HIV/HCV coinfected people, can lead them to death. The management of the treatment of patients is needed to monitor and, if possible, prevent complications related to adverse effects.

show abstract

1172 Genetic Variation in Il28b Rs 12979860 and Response to HCV-Specific Treatment in HCV/Hiv Co-Infected Patients

Cited by 3 publications

References 0 publications

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

Tratamiento de la hepatitis por virus C en pacientes coinfectados por el virus de la inmunodeficiencia humana

HIV/HCV Coinfection: Considerations about Treatment

Contact Info

Product

Resources

About